670 related articles for article (PubMed ID: 33780933)
21. Effectiveness and Safety of Sacubitril/Valsartan in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.
Mou Y; Qin L; Wang L; Guo Y; Zhang X; Yu J
Altern Ther Health Med; 2024 Apr; 30(4):190-197. PubMed ID: 37917889
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and Safety of Sacubitril/Valsartan Compared With ACEI/ARB on Health-Related Quality of Life in Heart Failure Patients: A Meta-Analysis.
Yang HR; Xu XD; Shaikh AS; Zhou BT
Ann Pharmacother; 2023 Aug; 57(8):907-917. PubMed ID: 36475871
[TBL] [Abstract][Full Text] [Related]
23. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF.
Böhm M; Young R; Jhund PS; Solomon SD; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Swedberg K; Zile MR; Packer M; McMurray JJV
Eur Heart J; 2017 Apr; 38(15):1132-1143. PubMed ID: 28158398
[TBL] [Abstract][Full Text] [Related]
24. Safety and efficacy of ARNI (valsartan/sacubitril) vs ACEI (enalapril) in acute heart failure - A prospective observational study.
Bhat TS; Hafeez I; Tak SF; Mattoo A; Patigaroo AR; Khan A; Lone AA; Beig JR
Indian Heart J; 2022; 74(3):178-181. PubMed ID: 35483448
[TBL] [Abstract][Full Text] [Related]
25. Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF.
McMurray JJV; Jackson AM; Lam CSP; Redfield MM; Anand IS; Ge J; Lefkowitz MP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Rizkala AR; Sabarwal SV; Shah AM; Shah SJ; Shi VC; van Veldhuisen DJ; Zannad F; Zile MR; Cikes M; Goncalvesova E; Katova T; Kosztin A; Lelonek M; Sweitzer N; Vardeny O; Claggett B; Jhund PS; Solomon SD
Circulation; 2020 Feb; 141(5):338-351. PubMed ID: 31736337
[TBL] [Abstract][Full Text] [Related]
26. Evaluating the Safety and Tolerability of Sacubitril/Valsartan for HFrEF Managed Within a Pharmacist Clinic.
Pogge EK; Davis LE
Am J Cardiovasc Drugs; 2018 Apr; 18(2):143-151. PubMed ID: 29455335
[TBL] [Abstract][Full Text] [Related]
27. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial.
Solomon SD; Rizkala AR; Gong J; Wang W; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Shi VC; Lefkowitz MP; McMurray JJV
JACC Heart Fail; 2017 Jul; 5(7):471-482. PubMed ID: 28662936
[TBL] [Abstract][Full Text] [Related]
28. Lower Hospitalization and Healthcare Costs With Sacubitril/Valsartan Versus Angiotensin-Converting Enzyme Inhibitor or Angiotensin-Receptor Blocker in a Retrospective Analysis of Patients With Heart Failure.
Albert NM; Swindle JP; Buysman EK; Chang C
J Am Heart Assoc; 2019 May; 8(9):e011089. PubMed ID: 31023122
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of sacubitril/valsartan compared with enalapril in patients with chronic heart failure and reduced ejection fraction: Results from PARADIGM-HF India sub-study.
Jain AR; Aggarwal RK; Rao NS; Billa G; Kumar S
Indian Heart J; 2020; 72(6):535-540. PubMed ID: 33357641
[TBL] [Abstract][Full Text] [Related]
30. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
Velazquez EJ; Morrow DA; DeVore AD; Duffy CI; Ambrosy AP; McCague K; Rocha R; Braunwald E;
N Engl J Med; 2019 Feb; 380(6):539-548. PubMed ID: 30415601
[TBL] [Abstract][Full Text] [Related]
31. Effect of sacubitril/valsartan and ACEI/ARB on glycaemia and the development of diabetes: a systematic review and meta-analysis of randomised controlled trials.
Wang R; Ye H; Zhao Y; Wei J; Wang Y; Zhang X; Wang L
BMC Med; 2022 Dec; 20(1):487. PubMed ID: 36527023
[TBL] [Abstract][Full Text] [Related]
32. NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction: TRANSITION Study.
Pascual-Figal D; Wachter R; Senni M; Bao W; Noè A; Schwende H; Butylin D; Prescott MF;
JACC Heart Fail; 2020 Oct; 8(10):822-833. PubMed ID: 32800508
[TBL] [Abstract][Full Text] [Related]
33. Utilization of sacubitril/valsartan in patients with heart failure with reduced ejection fraction: real-world data from the ARIADNE registry.
Zeymer U; Clark AL; Barrios V; Damy T; Drożdż J; Fonseca C; Lund LH; Kalus S; Ferber PC; Hussain RI; Koch C; Maggioni AP
Eur Heart J Qual Care Clin Outcomes; 2022 Jun; 8(4):469-477. PubMed ID: 33725113
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of early initiation of Sacubitril/Valsartan in patients after acute myocardial infarction: A meta-analysis.
Zhao J; Zeng Y; Shen X
Clin Cardiol; 2021 Oct; 44(10):1354-1359. PubMed ID: 34464468
[TBL] [Abstract][Full Text] [Related]
35. Sacubitril/valsartan vs. angiotensin receptor inhibition in heart failure: a real-world study in Taiwan.
Chang PC; Wang CL; Hsiao FC; Wen MS; Huang CY; Chou CC; Chu PH
ESC Heart Fail; 2020 Oct; 7(5):3003-3012. PubMed ID: 32720478
[TBL] [Abstract][Full Text] [Related]
36. Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared With Valsartan in HFpEF.
Vaduganathan M; Claggett BL; Desai AS; Anker SD; Perrone SV; Janssens S; Milicic D; Arango JL; Packer M; Shi VC; Lefkowitz MP; McMurray JJV; Solomon SD
J Am Coll Cardiol; 2020 Jan; 75(3):245-254. PubMed ID: 31726194
[TBL] [Abstract][Full Text] [Related]
37. Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy.
Okumura N; Jhund PS; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Swedberg K; Zile MR; Solomon SD; Packer M; McMurray JJ;
Circ Heart Fail; 2016 Sep; 9(9):. PubMed ID: 27618854
[TBL] [Abstract][Full Text] [Related]
38. Long-Term Mortality and Morbidity Related to Congestive Heart Failure with Reduced Ejection Fraction (CHFrEF) in Palestinian Patients Maintained on Submaximal Sacubitril/Valsartan Doses: A Pilot Study.
Aqel R; Alzughayyar TZ; Abukhalaf SA; Misk RA; Zalloum JS
J Renin Angiotensin Aldosterone Syst; 2021; 2021():1829873. PubMed ID: 35027945
[TBL] [Abstract][Full Text] [Related]
39. Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized With Heart Failure and Reduced Ejection Fraction.
Fudim M; Sayeed S; Xu H; Matsouaka RA; Heidenreich PA; Velazquez EJ; Yancy CW; Fonarow GC; Hernandez AF; DeVore AD
Circ Heart Fail; 2020 Apr; 13(4):e006645. PubMed ID: 32248695
[TBL] [Abstract][Full Text] [Related]
40. The effect of Sacubitril/Valsartan on cardiac function and cardiac remodeling in patients with heart failure with reduced ejection fraction.
Chen F; Tian G; Bai X; Li J; Yuan Z
Ann Palliat Med; 2021 Aug; 10(8):8684-8691. PubMed ID: 34488357
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]